

Gianni Pezzoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9414906/publications.pdf>

Version: 2024-02-01

211
papers

13,270
citations

22153

59
h-index

28297

105
g-index

211
all docs

211
docs citations

211
times ranked

15433
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical correlates of serum 25-hydroxyvitamin D in Parkinson's disease. <i>Nutritional Neuroscience</i> , 2022, 25, 1128-1136.	3.1	11
2	Resting energy expenditure in Parkinson's disease patients under dopaminergic treatment. <i>Nutritional Neuroscience</i> , 2022, 25, 246-255.	3.1	3
3	Astrocytes expressing Vitamin D-activating enzyme identify Parkinson's disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 703-713.	3.9	10
4	Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk. <i>Movement Disorders</i> , 2022, 37, 1202-1210.	3.9	17
5	Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease. <i>Neurology</i> , 2022, 99, .	1.1	25
6	Vitamin D Status and Parkinson's Disease. <i>Brain Sciences</i> , 2022, 12, 790.	2.3	18
7	Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. <i>Nutrition</i> , 2021, 82, 111055.	2.4	57
8	Does Gut Microbiota Influence the Course of Parkinson's Disease? A 3-Year Prospective Exploratory Study in de novo Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 159-170.	2.8	27
9	Poly (ADP-ribose) polymerase 1 and Parkinson's disease: A study in post-mortem human brain. <i>Neurochemistry International</i> , 2021, 144, 104978.	3.8	8
10	Impaired reach-to-grasp kinematics in parkinsonian patients relates to dopamine-dependent, subthalamic beta bursts. <i>Npj Parkinson's Disease</i> , 2021, 7, 53.	5.3	14
11	The Association between α -Synuclein and α -Tubulin in Brain Synapses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9153.	4.1	10
12	Screening of LRP10 mutations in Parkinson's disease patients from Italy. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 17-21.	2.2	5
13	Safety and Effectiveness of Cell Therapy in Neurodegenerative Diseases: Take-Home Messages From a Pilot Feasibility Phase I Study of Progressive Supranuclear Palsy. <i>Frontiers in Neuroscience</i> , 2021, 15, 723227.	2.8	1
14	The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, , 089198872110600.	2.3	0
15	The imbalance between dynamic and stable microtubules underlies neurodegeneration induced by 2,5-hexanedione. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165581.	3.8	8
16	A human minisatellite hosts an alternative transcription start site for NPRL3 driving its expression in a repeat number-dependent manner. <i>Human Mutation</i> , 2020, 41, 807-824.	2.5	6
17	A rapid and low-cost test for screening the most common Parkinson's disease-related GBA variants. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 138-141.	2.2	7
18	Saposin D variants are not a common cause of familial Parkinson's disease among Italians. <i>Brain</i> , 2020, 143, e71-e71.	7.6	7

#	ARTICLE	IF	CITATIONS
19	Predictors of COVID-19 outcome in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 134-137.	2.2	63
20	Gait initiation in progressive supranuclear palsy: brain metabolic correlates. <i>NeuroImage: Clinical</i> , 2020, 28, 102408.	2.7	21
21	Inhibitory control dysfunction in parkinsonian impulse control disorders. <i>Brain</i> , 2020, 143, 3734-3747.	7.6	13
22	Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19. <i>Movement Disorders</i> , 2020, 35, 1498-1498.	3.9	2
23	Iron deposition in Parkinsonisms: A Quantitative Susceptibility Mapping study in the deep grey matter. <i>European Journal of Radiology</i> , 2020, 133, 109394.	2.6	15
24	COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy. <i>Movement Disorders</i> , 2020, 35, 1089-1093.	3.9	129
25	Could <i>Mucuna pruriens</i> be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 3-7.	2.2	16
26	Brain metabolic alterations herald falls in patients with Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 579-583.	3.7	9
27	Gait Initiation in Parkinson's Disease: Impact of Dopamine Depletion and Initial Stance Condition. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 137.	4.1	32
28	Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms. <i>Frontiers in Neuroscience</i> , 2020, 14, 624.	2.8	17
29	Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa. <i>Brain</i> , 2020, 143, 2490-2501.	7.6	87
30	Î±-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson's disease. <i>Brain</i> , 2020, 143, 920-931.	7.6	41
31	The SPID-GBA study. <i>Neurology: Genetics</i> , 2020, 6, e523.	1.9	37
32	Author response: Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome. <i>Neurology</i> , 2020, 95, 143-143.	1.1	0
33	Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decision-making. <i>European Journal of Neuroscience</i> , 2019, 50, 2392-2400.	2.6	7
34	Nutritional characterisation of <i>Zambian Moringa oleifera</i> : acceptability and safety of short-term daily supplementation in a group of malnourished girls. <i>International Journal of Food Sciences and Nutrition</i> , 2019, 70, 107-115.	2.8	21
35	Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome. <i>Neurology</i> , 2019, 93, e485-e496.	1.1	30
36	Freezing of gait in Parkinson's disease reflects a sudden derangement of locomotor network dynamics. <i>Brain</i> , 2019, 142, 2037-2050.	7.6	96

#	ARTICLE	IF	CITATIONS
37	Neuronal microtubules and proteins linked to Parkinson's disease: a relevant interaction?. <i>Biological Chemistry</i> , 2019, 400, 1099-1112.	2.5	25
38	Resting state oscillations suggest a motor component of Parkinson's Impulse Control Disorders. <i>Clinical Neurophysiology</i> , 2019, 130, 2065-2075.	1.5	4
39	Using global team science to identify genetic parkinson's disease worldwide. <i>Annals of Neurology</i> , 2019, 86, 153-157.	5.3	26
40	Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient. <i>Movement Disorders</i> , 2019, 34, 757-759.	3.9	28
41	Sit-to-walk performance in Parkinson's disease: A comparison between faller and non-faller patients. <i>Clinical Biomechanics</i> , 2019, 63, 140-146.	1.2	22
42	Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. <i>Movement Disorders</i> , 2019, 34, 396-405.	3.9	252
43	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. <i>Movement Disorders</i> , 2019, 34, 9-21.	3.9	73
44	Excitability of the supplementary motor area in Parkinson's disease depends on subcortical damage. <i>Brain Stimulation</i> , 2019, 12, 152-160.	1.6	35
45	Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2670-2679.	3.6	8
46	Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 11.	5.3	169
47	Daily intake of <i>Mucuna pruriens</i> in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 60-66.	2.2	39
48	Personality Traits and Cortical Activity Affect Gambling Behavior in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 341-352.	2.8	7
49	Multiple system atrophy and CAG repeat length: A genetic screening of polyglutamine disease genes in Italian patients. <i>Neuroscience Letters</i> , 2018, 678, 37-42.	2.1	10
50	Gambling behavior in Parkinson's Disease: Impulsivity, reward mechanism and cortical brain oscillations. <i>Psychiatry Research</i> , 2018, 270, 974-980.	3.3	12
51	Mitochondrial dysfunction in Parkinsonian mesenchymal stem cells impairs differentiation. <i>Redox Biology</i> , 2018, 14, 474-484.	9.0	104
52	Parkin absence accelerates microtubule aging in dopaminergic neurons. <i>Neurobiology of Aging</i> , 2018, 61, 66-74.	3.1	43
53	Evaluating psychiatric symptoms in Parkinson's Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 131-137.	4.8	24
54	The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 64.	2.9	32

#	ARTICLE	IF	CITATIONS
55	Phase matters: A role for the subthalamic network during gait. PLoS ONE, 2018, 13, e0198691.	2.5	38
56	Cortical response to levodopa in Parkinson's disease patients with dyskinesias. European Journal of Neuroscience, 2018, 48, 2362-2373.	2.6	9
57	Dietary habits in Parkinson's disease: Adherence to Mediterranean diet. Parkinsonism and Related Disorders, 2017, 42, 40-46.	2.2	58
58	Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. Journal of Neurology, 2017, 264, 1254-1263.	3.6	52
59	A focus on Rome III criteria for the assessment of constipation in Parkinson's disease. Movement Disorders, 2017, 32, 630-630.	3.9	4
60	Protein redistribution diet in a case of tyrosine hydroxylase enzyme deficiency. Movement Disorders, 2017, 32, 794-795.	3.9	1
61	<i>DNAJC12</i> and dopa-responsive nonprogressive parkinsonism. Annals of Neurology, 2017, 82, 640-646.	5.3	60
62	Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study. Annals of Clinical and Translational Neurology, 2017, 4, 632-639.	3.7	15
63	<i>Mucuna pruriens</i> in Parkinson disease. Neurology, 2017, 89, 432-438.	1.1	79
64	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. European Radiology, 2017, 27, 2665-2675.	4.5	66
65	Dietary habits and neurological features of Parkinson's disease patients: Implications for practice. Clinical Nutrition, 2017, 36, 1054-1061.	5.0	74
66	Divergent Thinking in Parkinsonism: A Case-Control Study. Frontiers in Neurology, 2017, 8, 534.	2.4	7
67	Factors influencing psychological well-being in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0189682.	2.5	32
68	Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments. PLoS ONE, 2017, 12, e0170927.	2.5	45
69	Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?. Frontiers in Aging Neuroscience, 2016, 8, 192.	3.4	14
70	Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Frontiers in Aging Neuroscience, 2016, 8, 196.	3.4	146
71	Striatal Dopaminergic Innervation Regulates Subthalamic Beta-Oscillations and Cortical-Subcortical Coupling during Movements: Preliminary Evidence in Subjects with Parkinson's Disease. Frontiers in Human Neuroscience, 2016, 10, 611.	2.0	45
72	Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. Journal of Neural Transmission, 2016, 123, 1435-1442.	2.8	61

#	ARTICLE	IF	CITATIONS
73	Creative Thinking, Professional Artists, and Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 239-246.	2.8	16
74	<i>Mucuna pruriens</i> for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. <i>Journal of the Neurological Sciences</i> , 2016, 365, 175-180.	0.6	44
75	Sarcopenia and Dynapenia in Patients With Parkinsonism. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 640-646.	2.5	53
76	Probiotics and prebiotic fiber for constipation associated with Parkinson disease. <i>Neurology</i> , 2016, 87, 1274-1280.	1.1	264
77	Survival and dementia in GBA-associated Parkinson's disease: The mutation matters. <i>Annals of Neurology</i> , 2016, 80, 662-673.	5.3	312
78	Î±-Synuclein is a Novel Microtubule Dynamase. <i>Scientific Reports</i> , 2016, 6, 33289.	3.3	79
79	Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry. <i>Journal of Neurochemistry</i> , 2016, 138, 339-353.	3.9	53
80	Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. <i>Journal of Translational Medicine</i> , 2016, 14, 127.	4.4	41
81	Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 96-103.	2.2	26
82	Dementia in Parkinson's disease: Is male gender a risk factor?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 67-72.	2.2	52
83	Intensive Rehabilitation Enhances Lymphocyte BDNF-TrkB Signaling in Patients With Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 411-418.	2.9	46
84	Mechanical Energy Recovery during Walking in Patients with Parkinson Disease. <i>PLoS ONE</i> , 2016, 11, e0156420.	2.5	32
85	Linking microtubules to Parkinson's disease: the case of parkin. <i>Biochemical Society Transactions</i> , 2015, 43, 292-296.	3.4	24
86	Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders. <i>Movement Disorders</i> , 2015, 30, 696-704.	3.9	35
87	Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	9.0	272
88	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. <i>Journal of Neural Transmission</i> , 2015, 122, 799-808.	2.8	7
89	Increased urinary indoxyl sulfate (indican): New insights into gut dysbiosis in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 389-393.	2.2	82
90	Endothelial progenitor cells: Cardiovascular protection in Parkinson's disease?. <i>International Journal of Cardiology</i> , 2015, 197, 200-202.	1.7	2

#	ARTICLE	IF	CITATIONS
91	Parkinson's disease beyond 20 years. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 849-855.	1.9	55
92	An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics, 2015, 16, 55-64.	1.4	20
93	Intensive Rehabilitation Treatment in Early Parkinson's Disease. Neurorehabilitation and Neural Repair, 2015, 29, 123-131.	2.9	137
94	Differences in Muscle Strength in Parkinsonian Patients Affected on the Right and Left Side. PLoS ONE, 2015, 10, e0121251.	2.5	23
95	Effects of mechanical stimulation of the feet on gait and cardiovascular autonomic control in Parkinson's disease. Journal of Applied Physiology, 2014, 116, 495-503.	2.5	31
96	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain, 2014, 137, 2731-2742.	7.6	251
97	Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors. Parkinsonism and Related Disorders, 2014, 20, 1382-1387.	2.2	93
98	Novel <i>DYT11</i> gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. Neurology, 2014, 83, 1155-1162.	1.1	22
99	Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. Journal of Translational Medicine, 2014, 12, 14.	4.4	30
100	Intensive Rehabilitation Increases BDNF Serum Levels in Parkinsonian Patients. Neurorehabilitation and Neural Repair, 2014, 28, 163-168.	2.9	118
101	Reversible dopamine transporter reduction in drug-induced parkinsonism. Movement Disorders, 2014, 29, 575-577.	3.9	16
102	<i>LRRK2</i> G2019S mutation is not associated with an increased cancer risk: A kinship cohort study. Movement Disorders, 2014, 29, 1325-1326.	3.9	11
103	Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 1215-1220.	2.2	63
104	Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. Parkinsonism and Related Disorders, 2014, 20, 1181-1185.	2.2	3
105	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
106	Multiple compulsive behaviors in multiple system atrophy: The importance of predisposition to addiction. Parkinsonism and Related Disorders, 2014, 20, 355-357.	2.2	8
107	Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 311-318.	1.9	57
108	Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology, 2014, 83, 215-220.	1.1	98

#	ARTICLE	IF	CITATIONS
109	LRRK2 mutations in Parkinson's disease: Confirmation of a gender effect in the Italian population. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 911-914.	2.2	40
110	Corrigendum to "The sleeve gastrectomy intervention to treat morbid obesity in a parkinson's disease patient" [Clin Nutr 32 (3) (2013) 476-478]. <i>Clinical Nutrition</i> , 2014, 33, 928.	5.0	0
111	Remote control of induced dopaminergic neurons in parkinsonian rats. <i>Journal of Clinical Investigation</i> , 2014, 124, 3215-3229.	8.2	104
112	Validation of the Italian version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013, 34, 683-687.	1.9	123
113	Microtubule Alterations Occur Early in Experimental Parkinsonism and The Microtubule Stabilizer Epothilone D Is Neuroprotective. <i>Scientific Reports</i> , 2013, 3, 1837.	3.3	103
114	Nutritional status and dietary habits in Parkinson's disease patients in Ghana. <i>Nutrition</i> , 2013, 29, 470-473.	2.4	14
115	Exposure to pesticides or solvents and risk of Parkinson disease. <i>Neurology</i> , 2013, 80, 2035-2041.	1.1	238
116	Effectiveness of an intensive rehabilitation treatment on different Parkinson's disease subtypes. <i>NeuroRehabilitation</i> , 2013, 33, 299-303.	1.3	12
117	Reproductive factors and clinical features of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1094-1099.	2.2	41
118	Asymmetry and freezing of gait in parkinsonian patients. <i>Journal of Neurology</i> , 2013, 260, 71-76.	3.6	59
119	DJ1 analysis in a large cohort of Italian early onset Parkinson Disease patients. <i>Neuroscience Letters</i> , 2013, 557, 165-170.	2.1	11
120	Cardiometabolic factors and disease duration in patients with Parkinson's disease. <i>Nutrition</i> , 2013, 29, 1331-1335.	2.4	24
121	The sleeve gastrectomy intervention to treat morbid obesity in a Parkinson's disease patient. <i>Clinical Nutrition</i> , 2013, 32, 476-478.	5.0	3
122	Rapid Generation of Functional Dopaminergic Neurons From Human Induced Pluripotent Stem Cells Through a Single-Step Procedure Using Cell Lineage Transcription Factors. <i>Stem Cells Translational Medicine</i> , 2013, 2, 473-479.	3.3	81
123	The Beneficial Role of Intensive Exercise on Parkinson Disease Progression. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2013, 92, 523-532.	1.4	74
124	Nutritional risk and gastrointestinal dysautonomia symptoms in Parkinson's disease outpatients hospitalised on a scheduled basis. <i>British Journal of Nutrition</i> , 2013, 110, 347-353.	2.3	43
125	Diabetes and risk of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 257-261.	3.9	38
126	Short- and Long-Term Efficacy of Intensive Rehabilitation Treatment on Balance and Gait in Parkinsonian Patients: A Preliminary Study with a 1-Year Followup. <i>Parkinson's Disease</i> , 2013, 2013, 1-5.	1.1	24

#	ARTICLE	IF	CITATIONS
127	[123I]FP-CIT SPECT in atypical degenerative parkinsonism. <i>Imaging in Medicine</i> , 2012, 4, 411-421.	0.0	3
128	Meningioma with intense ¹²³ I FP-CIT uptake. <i>Movement Disorders</i> , 2012, 27, 1744-1745.	3.9	3
129	SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 257-262.	2.2	51
130	Corrigendum to "Increased Levels of Endothelial Progenitor Cells in Parkinson's Disease" [Parkinsonism Rel Dis 17 (2011) 651-652]. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 807.	2.2	1
131	Low cardiometabolic risk in Parkinson's disease is independent of nutritional status, body composition and fat distribution. <i>Clinical Nutrition</i> , 2012, 31, 699-704.	5.0	41
132	Microtubule Destabilization Is Shared by Genetic and Idiopathic Parkinson's Disease Patient Fibroblasts. <i>PLoS ONE</i> , 2012, 7, e37467.	2.5	43
133	The Influence of Dopaminergic Striatal Innervation on Upper Limb Locomotor Synergies. <i>PLoS ONE</i> , 2012, 7, e51464.	2.5	17
134	Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with 6-Month Followup. <i>Parkinson's Disease</i> , 2012, 2012, 1-4.	1.1	11
135	Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2). <i>Acta Neuropathologica</i> , 2012, 123, 901-903.	7.7	22
136	The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 800-801.	3.9	15
137	Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. <i>Journal of Neurology</i> , 2012, 259, 569-570.	3.6	24
138	Association analysis of PARP1 polymorphisms with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 701-704.	2.2	5
139	Mutational screening and zebrafish functional analysis of GICYF2 as a Parkinson-disease gene. <i>Neurobiology of Aging</i> , 2011, 32, 1994-2005.	3.1	16
140	Regression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine Agonists. <i>Cardiovascular Therapeutics</i> , 2011, 29, 404-410.	2.5	17
141	Analysis of Nucleotide Variations in Genes of Iron Management in Patients of Parkinson's Disease and Other Movement Disorders. <i>Parkinson's Disease</i> , 2011, 2011, 1-6.	1.1	4
142	Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients. <i>Parkinson's Disease</i> , 2011, 2011, 1-6.	1.1	7
143	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011, 6, e18301.	2.5	84
144	Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. <i>Nature</i> , 2011, 476, 224-227.	27.8	941

#	ARTICLE	IF	CITATIONS
145	A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. <i>Journal of Neurology</i> , 2011, 258, 579-585.	3.6	113
146	Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. <i>BMC Neurology</i> , 2011, 11, 88.	1.8	46
147	Oral high-calorie, low-protein supplements in a Parkinson's disease patient: A case report. <i>Movement Disorders</i> , 2011, 26, 354-355.	3.9	7
148	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. <i>Movement Disorders</i> , 2011, 26, 225-233.	3.9	109
149	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	3.9	139
150	Kinase-cohort analysis of <i>LRRK2</i> and <i>G2019S</i> penetrance in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2144-2145.	3.9	49
151	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2011, 70, 964-973.	5.3	168
152	Diabetes and Risk of Parkinson's Disease. <i>Diabetes Care</i> , 2011, 34, 2614-2623.	8.6	181
153	Cyclin-G-associated kinase modifies α -synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. <i>Human Molecular Genetics</i> , 2011, 20, 1478-1487.	2.9	60
154	Dopaminergic Striatal Innervation Predicts Interlimb Transfer of a Visuomotor Skill. <i>Journal of Neuroscience</i> , 2011, 31, 14458-14462.	3.6	32
155	A role for locus coeruleus in Parkinson tremor. <i>Frontiers in Human Neuroscience</i> , 2011, 5, 179.	2.0	51
156	VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 87-94.	2.6	12
157	Cognitive status of patients with Parkinson's disease and pathological gambling. <i>Journal of Neurology</i> , 2010, 257, 247-252.	3.6	49
158	Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. <i>Neurological Sciences</i> , 2010, 31, 35-40.	1.9	40
159	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. <i>Neurobiology of Disease</i> , 2010, 39, 98-104.	4.4	136
160	Role of an electronic armband in motor function monitoring in patients with Parkinson's disease. <i>Nutrition</i> , 2010, 26, 240-242.	2.4	25
161	Imaging essential tremor. <i>Movement Disorders</i> , 2010, 25, 679-686.	3.9	80
162	Low-protein and protein redistribution diets for Parkinson's disease patients with motor fluctuations: A systematic review. <i>Movement Disorders</i> , 2010, 25, 2021-2034.	3.9	69

#	ARTICLE	IF	CITATIONS
163	Controlled-protein dietary regimens for Parkinson's disease. <i>Nutritional Neuroscience</i> , 2010, 13, 29-32.	3.1	20
164	The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 65-67.	1.4	12
165	Î±-Synuclein multiplication analysis in Italian familial Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 228-231.	2.2	36
166	Levodopa in Parkinson's disease: from the past to the future. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 627-635.	1.8	54
167	Major nutritional issues in the management of Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1881-1892.	3.9	183
168	Genomewide association study for onset age in Parkinson disease. <i>BMC Medical Genetics</i> , 2009, 10, 98.	2.1	104
169	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 140-146.	1.4	40
170	Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 327-328.	2.2	32
171	Screening for the Presence of FMR1 Premutation Alleles in Women With Parkinsonism. <i>Archives of Neurology</i> , 2009, 66, 244-9.	4.5	27
172	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. <i>Human Genetics</i> , 2008, 124, 95-99.	3.8	34
173	The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 411-415.	3.9	131
174	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565.	2.5	74
175	A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset. <i>Neurobiology of Disease</i> , 2008, 31, 102-109.	4.4	24
176	Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease. <i>American Journal of Human Genetics</i> , 2008, 82, 822-833.	6.2	164
177	Parkin analysis in early onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 326-333.	2.2	42
178	HFE gene mutations in a population of Italian Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 426-430.	2.2	24
179	Mini Nutritional Assessment in patients with Parkinson's disease: correlation between worsening of the malnutrition and increasing number of disease-years. <i>Nutritional Neuroscience</i> , 2008, 11, 128-134.	3.1	48
180	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1604-11.	4.5	127

#	ARTICLE	IF	CITATIONS
181	Striatal dopamine transporter abnormalities in patients with essential tremor. <i>Nuclear Medicine Communications</i> , 2008, 29, 349-353.	1.1	69
182	Diet with LPP for renal patients increases daily energy expenditure and improves motor function in Parkinsonian patients with motor fluctuations. <i>Nutritional Neuroscience</i> , 2007, 10, 129-135.	3.1	17
183	Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2007, 356, 39-46.	27.0	824
184	Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism. <i>Archives of Neurology</i> , 2007, 64, 1002.	4.5	33
185	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>NeuroReport</i> , 2007, 18, 1499-1502.	1.2	59
186	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 290-294.	2.2	61
187	Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. <i>Human Mutation</i> , 2007, 28, 98-98.	2.5	66
188	Extradural motor cortex stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 111-114.	3.9	46
189	Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. <i>Movement Disorders</i> , 2007, 22, 1145-1149.	3.9	241
190	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 410-419.	2.2	106
191	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.	2.8	152
192	Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. <i>Movement Disorders</i> , 2006, 21, 417-418.	3.9	28
193	Protein intake in Parkinsonian patients using the EPIC food frequency questionnaire. <i>Movement Disorders</i> , 2006, 21, 1229-1231.	3.9	37
194	Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. <i>Movement Disorders</i> , 2006, 21, 1119-1122.	3.9	101
195	Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. <i>Movement Disorders</i> , 2006, 21, 1144-1147.	3.9	41
196	Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1682-1687.	3.9	44
197	Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 826.	4.5	147
198	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005, 13, 748-752.	2.8	197

#	ARTICLE	IF	CITATIONS
199	The Neuromelanin of Human Substantia Nigra: Physiological and Pathogenic Aspects. <i>Pigment Cell & Melanoma Research</i> , 2004, 17, 610-617.	3.6	109
200	Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. <i>Movement Disorders</i> , 2003, 18, 1337-1340.	3.9	132
201	Thin Section MR Study of the Basal Ganglia in the Differential Diagnosis Between Striatonigral Degeneration and Parkinson Disease. <i>Journal of Computer Assisted Tomography</i> , 2002, 26, 266-271.	0.9	49
202	Tc ^{99m} ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2002, 17, 1265-1270.	3.9	86
203	T1 and T2 in the Brain of Healthy Subjects, Patients with Parkinson Disease, and Patients with Multiple System Atrophy: Relation to Iron Content. <i>Radiology</i> , 1999, 211, 489-495.	7.3	314
204	Effect of nerve growth factor in adrenal autografts in parkinsonism. <i>Annals of Neurology</i> , 1990, 27, 341-342.	5.3	109
205	n-Hexane induces Parkinsonism in rodents. <i>Brain Research</i> , 1990, 531, 355-357.	2.2	36
206	Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain – Possible mechanisms of milacemide antimyoclonic property in the p,p'-DDT-induced myoclonus. <i>Pharmacology Biochemistry and Behavior</i> , 1989, 32, 993-1001.	2.9	14
207	Monoamine oxidase inhibitory properties of milacemide in rats. <i>Life Sciences</i> , 1989, 44, 1059-1066.	4.3	8
208	Glycine involvement in DDT-induced myoclonus. <i>Movement Disorders</i> , 1988, 3, 77-87.	3.9	9
209	Cryopreservation of human fetal adrenal medullary cells. <i>Brain Research</i> , 1988, 454, 383-386.	2.2	10
210	Primary Cultures of Human Caudate Nucleus. <i>Stereotactic and Functional Neurosurgery</i> , 1988, 51, 10-20.	1.5	8
211	Human Fetal Adrenal Medulla for Transplantation in Parkinsonian Patients. <i>Annals of the New York Academy of Sciences</i> , 1987, 495, 771-773.	3.8	4